Many state Medicaid programs still limit access due to cost concerns, according to the Center for Health Law and Policy Innovation.
Over the past two years, state Medicaid programs have done a better job of disclosing information about access to hepatitis C medicines and are also making progress in reducing or eliminating restrictions that pose a barrier to treatment, according to a new preliminary analysis.
